What is known and objective: In older patients, multiple chronic conditions lead to the intake of multiple medications and a higher risk of adverse drug events. The exposure to inappropriate medications in older patients with bleeding disorders is poorly explored. The aim of this study was to describe the exposure to potentially inappropriate medications (PIMs) and medications with anticholinergic and sedative properties in older community‐dwelling patients with haemophilia or von Willebrand Disease (VWD).
Methods
The M’HEMORRH‐AGE study (Medication in AGEd patients with HAEMORRHagic disease) is a multicentre prospective observational study. Community‐dwelling patients over 65 years with haemophilia or VWD were included in the study. PIMs were identified using the EU(7)‐PIM list, and the anticholinergic and sedative drug exposure was measured using the Drug Burden Index.
Results and discussion
142 older community‐dwelling patients with haemophilia (n = 89) or VWD (n = 53) were included (mean age: 72.8 ± 5.8 years). PIMs were used by 45.8% of older patients and were mainly represented by cardiovascular (34.9%), nervous systems (26.7%) and alimentary tract and metabolism PIMs (25.6%). Regarding anticholinergic and/or sedative medications, 37.3% of older patients were exposed mainly due to nervous system medications (68.3%), for example analgesics.
What is new and conclusion: The M’HEMORRH‐AGE study showed the exposure to PIMs and anticholinergic/sedative medications was high in older community‐dwelling patients with haemophilia or VWD. Interventions focusing on deprescription of these inappropriate medications should be conducted in this specific population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.